Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04933682
PHASE1

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Sponsor: Alexion Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This is a 2-part, open label, fixed-sequence study to evaluate the potential drug interaction between ALXN2050 and fluconazole (Part 1), and between ALXN2050 and rifampin (Part 2) in healthy adult participants. Part 1 will be a 2-period, fixed-sequence study. Part 2 will be a single-period, fixed-sequence study.

Official title: A Phase 1 Two-Part Study to Evaluate the Potential Drug Interactions Between ALXN2050 and Fluconazole, and Between ALXN2050 and Rifampin in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2021-06-07

Completion Date

2021-08-23

Last Updated

2026-07-16

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

ALXN2050

Oral tablet.

DRUG

Fluconazole

Oral tablet.

DRUG

Rifampin

Oral capsule.

Locations (1)

Clinical Trial Site

Tempe, Arizona, United States